Man Group plc Invests $3.33 Million in Stryker Corporation $SYK

Man Group plc acquired a new stake in shares of Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,568 shares of the medical technology company’s stock, valued at approximately $3,327,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP grew its stake in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Stryker in the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the 2nd quarter worth $253,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Down 1.9%

Shares of SYK stock opened at $324.32 on Tuesday. The business has a 50-day moving average of $329.49 and a 200 day moving average of $331.03. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock has a market capitalization of $124.40 billion, a PE ratio of 33.61, a P/E/G ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Analysts Set New Price Targets

SYK has been the subject of several research reports. JPMorgan Chase & Co. cut their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Piper Sandler reduced their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Finally, Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In other news, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.